Jan 19 2011
Provider of medical imaging systems and machine vision software STI Medical Systems recently declared that the US Food and Drug Administration has approved its ImageSense technology that will be utilized in colposcopy.
The technology will help doctors upgrade the quality of imagery used to evaluate cervical neoplasia. Doctors have been using acetowhitening to help them detect parts of the cervix, which may have the disease. The new solution will help show a digital image revealing the color differences of the cervix before and after acetic acid has been applied while conducting a colposcopic test. The solution will show the relevant data by first converting the image into a digital one and then memorializing it, making it possible for the physician to view an area due to a transient effect.
The technology is being used on the UltraSightHD digital system. The integrated device offers a clinical workflow solution that incorporates DICOM-compatible imagery and a seamless Electronic Medical Records interface using its onboard touch-screen user interface. Cervical cancer is a major form of cancer resulting in the death of many women in developing nations. This is trouble because if detected in the early stages, it is curable in most cases. According to the World Health Organization, around 473,000 cases and 253,500 deaths are being reported each year. Lack of efficient screening procedures to detect pre-cancerous conditions or dysplasia is cited as a major factor, which could stem the cancer from spreading.
Source: http://www.bioportfolio.com/